OCON Therapeutics, an Israeli pioneer of intrauterine drug-delivery technology for treating severe uterine conditions, has secured $10m in funding to revolutionize drug delivery capabilities.
Led by CEO Keren Leshem, the company’s latest funding round was spearheaded by RH Capital, with a significant contribution from Features Capital, Exerte Partners, and Astia Angels.
According to OCON Therapeutics announcement on Monday, June 24, 2024, it will use the additional capital to enhance its capabilities to offer revolutionary treatment for uterine illnesses and establish a safer standard of care through a proprietary 3D drug delivery system.
OCON Therapeutics High-tech Innovations in Women’s Health
OCON Therapeutics is a leader in innovative drug delivery systems for treating devastating pathologies in the women’s health industry through its validated 3D stent drug delivery frame IUB® (Intra Uterine Ball), which has shown remarkable success in terms of safety and usability demonstrated in treating over 150,000 with its smart IUB Ballerine®.
With the latest capital infusion, OCON Therapeutics is looking to advance two ground-breaking assets: IUB SEAD® and IUB PRIMA®, explicitly designed for treating abnormal and heavy uterine bleeding affecting 15% of the global population.
This innovative technology will help alleviate suffering and present patients with multiple options for treatment, including long-term hormonal and short-term non-hormonal approaches. Combined, OCON Therapeutics innovative treatment approach will address the existing market gap of $35B and promote better health outcomes.
The company’s new investment is a vote of confidence by investors in its mission to provide revolutionary technologies for enhanced, safer, and effective treatment of prevalent intrauterine conditions.
